Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kezar Life Sciences Inc
KZR | US
0.18
USD0.01
5.88%
KZR | US
Loading StockChartView...
About Kezar Life Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
0.18
Open
0.17
High
0.18
Low
0.17
Kezar Life Sciences Inc. a clinical-stage biotechnology company engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616) a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications including lupus nephritis dermatomyositis and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261 a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco California.
View LessKZR | US
Risk
346.7
Sharpe
-0.84
Luna's Score
58/100
Recommendation
Hold
Luna says (KZR | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
68.9%1 month
346.7%3 months
203.4%6 months
146.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.40
Debt to equity
0.12
Debt to assets
0.10
Ent. to EBITDA
0.06
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-98.46M
MarketCap
13.13M
MarketCap(USD)
13.13M
Div. yield
-
Op. margin
-1.42K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-51.48
Short ratio
0.92
Short perc.
1.38
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.04
Range1M
7.26
Range3M
7.41
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
5.51
Price X volume
337.50K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.06 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.40 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 203.42 | 72.80 | Riskier |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 13.13M | 3.66B | Emerging |
